Core Viewpoint - MiMedx Group, Inc. will report its operating and financial results for Q4 and the full year ended December 31, 2025, on February 25, 2026, after market close [1] Group 1 - The senior management team will host a webcast and conference call to review the results at 4:30 p.m. Eastern Time on the same day [1] - The conference call can be accessed by U.S. investors at 877-407-6184 and international investors at 201-389-0877, with a conference ID of 13758446 [2] - A replay of the webcast will be available for approximately 30 days on the company's website following the event [2] Group 2 - MiMedx is a pioneer and leader in providing healing solutions, focusing on chronic and hard-to-heal wounds [3] - The company offers a leading portfolio of products for wound care, burn, and surgical sectors in healthcare [3] - MiMedx aims to be the leading global provider of healing solutions through relentless innovation to restore quality of life [3]

Company Overview - MiMedx (MDXG) shares increased by 8% in the last trading session, closing at $7, with higher trading volume compared to normal sessions [1] - The stock has shown a 0.5% gain over the past four weeks [1] - The rise in stock price is linked to investor optimism regarding the company's product portfolio in wound care, burn, and surgical sectors [1] Financial Performance - MiMedx is expected to report quarterly earnings of $0.06 per share, reflecting a year-over-year decline of 25% [2] - Revenue projections for the upcoming quarter are $89.28 million, which is a 2.4% increase from the same quarter last year [2] Earnings Estimates and Stock Movement - The consensus EPS estimate for MiMedx has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] - Historical data suggests that stock prices typically do not continue to rise without trends in earnings estimate revisions [3][4] Industry Context - MiMedx operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like PTC Therapeutics (PTCT) [5] - PTC Therapeutics has experienced a 0.7% decline in its stock price, with a return of -7.2% over the past month [5] - The consensus EPS estimate for PTC Therapeutics has decreased by 0.4% to -$1.07, representing a 7.8% increase from the previous year [6]